Clareo Health | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with a diagnosis of moderate to severe Ulcerative colitis (UC).
Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
Participants prescribed upadacitinib in accordance with the approved local label.
Participants able to understand and communicate with the investigator and comply with the requirements of the study.
Participants willing to continue with study documentation after cessation of upadacitinib.
Participants willing and able to participate in the collection of patient-reported data via cloud based mobile application using the provided smart device (iPhone).
You may not be if
Participants with any contraindication to upadacitinib.
Participants previously exposed to upadacitinib in a clinical trial.
Participants currently participating in interventional research (not including noninterventional study, postmarketing observational study (PMOS), or registry participation).
